Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

rozanolixizumab 8zilucoplan 7ravulizumab 6fludarabine 5efgartigimod alfa 5Cyclophosphamide 5telitacicept 3Prednisone 3inebilizumab 2Rituximab 2Pyridostigmine Bromide 2tofacitinib 1thymoglobulin 1talquetamab 1remibrutinib 1prednylidene 1iptacopan 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Therapeutics 1Tacrolimus 1Steroids 1Robotic Surgical Procedures 1Psychodrama 1Prednisolone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myasthenia Gravis × telitacicept × 1 year × Clear all
NCT06456580 2026-05-07

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Vor Biopharma

Phase 3 Recruiting
180 enrolled

Myasthenia Gravis

NCT07249632 2026-04-09

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

RemeGen Co., Ltd.

Phase 3 Recruiting
120 enrolled

Myasthenia Gravis

NCT07298928 2026-03-06

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

The Children's Hospital of Zhejiang University School of Medicine

Phase NA Not yet recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡